Sirtuin-activating compound
Sirtuin-activating compounds (STAC) are chemical compounds having an effect on sirtuins, a group of enzymes that use NAD+ to remove acetyl groups from proteins. They are caloric restriction mimetic candidates, molecules able to prevent aging-related diseases like Alzheimer's,[1] diabetes, and obesity.
Context
Leonard P. Guarente is recognized as the leading proponent of the hypothesis that caloric restriction slows aging by activation of Sirtuins.
STACs have been discovered by Konrad Howitz of Biomol Inc and biologist David Sinclair. In September 2003, Howitz and Sinclair et al. published a highly cited paper reporting that polyphenols such as resveratrol[2] activate human SIRT1 and extend the lifespan of budding yeast (Howitz et al., Nature, 2003). Other examples of such products are butein, piceatannol, isoliquiritigenin, fisetin, and quercetin.
Sirtris Pharmaceuticals, Sinclair's company, is currently developing drugs of this class like SRT1720.
References
- ↑ Gan, L. (2007). "Therapeutic potential of sirtuin-activating compounds in Alzheimer's disease". Drug News & Perspectives 20 (4): 233–239. doi:10.1358/dnp.2007.20.4.1101162. PMID 17637936.
- ↑ Kaeberlein, M.; McDonagh, T.; Heltweg, B.; Hixon, J.; Westman, E. A.; Caldwell, S. D.; Napper, A.; Curtis, R.; Distefano, P. S.; Fields, S.; Bedalov, A.; Kennedy, B. K. (2005). "Substrate-specific Activation of Sirtuins by Resveratrol". Journal of Biological Chemistry 280 (17): 17038–17045. doi:10.1074/jbc.M500655200. PMID 15684413.
External links
- http://pubs.acs.org/cen/coverstory/8234/8234aging.html
- Sirtris Pharmaceuticals' US patent for STAC
- Patent title: Novel Sirtuin Activating Compounds and Methods for Making the Same